Economic analysis has been my field ever since my early 20s, when I first discovered its complexities, potential, and power. At ERG, I’ve had the good fortune to work with great colleagues and clients to research issues and develop solutions for a wide variety of highly consequential public health questions. It has been a consistent joy to do work that is not only impactful but also a path of continuous learning and deepening.
Dr. Aylin Sertkaya, an ERG senior economist and vice president, designs and conducts economic analyses in support of a wide variety of public policy initiatives. Her work includes examining the costs and benefits of federal programs, particularly those that affect public health and safety, and requires close collaboration with scientists, policymakers, independent experts, and other stakeholders. She has led ERG’s economics team for over 10 years and ERG’S life cycle analysis team since 2008.
Aylin received a Recognition Award from the Food and Drug Administration for her work on effective quality systems and risk management approaches as part of FDA’s cGMPs (current Good Manufacturing Practices) in the 21st Century initiative. She has held several leadership positions in the Society for Risk Analysis, including president of SRA’s New England chapter, chair of its Economics and Benefit Analysis Specialty Group, and chair of numerous sessions at SRA meetings. She received the SRA Recognition Award for the workshop on expert elicitation methods that she has co-organized for SRA annual meetings since 2008. Aylin holds a Ph.D. in economics and a B.A. in physics and economics, with a minor in mathematics.